What is the clinical and cost effectiveness of human papillomavirus (HPV) testing, followed by liquid-based cytology triage of positive results, in primary screening for cervical cancer?
Abbotts J, McIntosh H
            Record ID 32013000464
            English
                                                            
                Authors' recommendations:
                In primary screening for cervical cancer, HPV testing followed by conventional cytology triage of positive results is highly sensitive and highly specific for the detection of CIN3+ (CIN3, carcinoma in situ and cervical cancer).
HPV testing followed by conventional cytology triage of positive results is more sensitive than cytology alone for the detection of CIN3+.
In women 35 years and older, HPV testing followed by conventional cytology triage of positive results is more specific than cytology alone. More evidence is required to establish relative specificity in women aged 20–35 years.
Primary HPV testing allows the screening interval to be safely extended to at least 6 years.
Primary HPV testing followed by conventional cytology triage of positive results, with a 5-year screening interval, may be cost effective compared with 3-yearly conventional cytology.
            
                                    
            Details
                        
                Project Status:
                Completed
            
                                                            
                Year Published:
                2012
            
                                    
                URL for published report:
                http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/shtg_-_evidence_notes/evidence_note_41.aspx
            
                                                            
                English language abstract:
                An English language summary is available
            
                                    
                Publication Type:
                Not Assigned
            
                                    
                Country:
                Scotland, United Kingdom
            
                                                
                        MeSH Terms
            - Papillomavirus Infections
 - Vaginal Smears
 - Mass Screening
 - Cost-Benefit Analysis
 - Cytodiagnosis
 
Contact
                        
                Organisation Name:
                Scottish Health Technologies Group
            
            
                        
                Contact Address:
                Scottish Health Technologies Group, Delta House, 50 West Nile Street, Glasgow, G1 2NP  Tel: 0141 225 6998
            
                                    
                Contact Name:
                his.shtg@nhs.scot
            
                                    
                Contact Email:
                his.shtg@nhs.scot
            
                                    
                Copyright:
                Healthcare Improvement Scotland
            
                    
                This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.